Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Latar belakang: Wanita Pekerja Seks (WPS) adalah populasi berisiko tinggi terhadap kejadian infeksi Human Immunodeficiency Virus (HIV). Persentase HIV pada WPS di Kota Jayapura kian mengalami peningkatan. Penelitian ini bertujuan untuk mengetahui faktor perilaku berisiko yang dapat mempengaruhi kejadian HIV pada WPS di Kota Jayapura. Metode: Sebanyak 361 WPS terpilih sebagai sampel melalui Time Location Sampling (TLS) dan Simple Random Sampling (SRS). Uji statistik yang digunakan pada penelitian ini adalah chi square dan regresi logistik. Variabel yang diikutsertakan dalam analisis ini meliputi variabel karakteristik demografi dan faktor perilaku berisiko yang dilakukan oleh WPS. Hasil: Persentase HIV pada penelitian ini diestimasikan mencapai 6.6%. Hasil analisis multivariabel menunjukkan variabel yang berhubungan dengan kejadian HIV diantaranya: (a) usia muda [p=0.03; 18-24 tahun: AOR=2.92; 95% CI=0.89-9.57 | 25-34 tahun: AOR= 3.93; 95% CI=1.33-11.63]; (b) usia seks pertama kali yang sangat muda [p=0.03; AOR=3.31; 95% CI=1.09-10.05]; (c) penggunaan kondom [p=0.03; AOR-0.10; 95% CI=0.01-0.81]. Kesimpulan: WPS yang berusia muda lebih berpotensi untuk terinfeksi HIV. Sementara WPS muda yang terinfeksi HIV, juga berisiko untuk terjangkit penyakit lain Human Papillomavirus (HPV) yang persisten dan dapat berujung pada kanker serviks. Oleh karena itu, pemeriksaan HIV dan penyakit menular seksual lain perlu dilakukan secara rutin untuk kalangan WPS agar dapat ditangani lebih dini. ......Background: Female Sex Workers (FSW) are high-risk population for Human Immunodeficiency Virus (HIV) infection. Prevalence of HIV among FSW in Jayapura has increased. This study aims to identify behavioral factor of HIV among FSW in Jayapura. Method: Data were collected on 361 FSW that selected by Time Location Sampling (TLS) and Simple Random Sampling (SRS). Chi-square and logistic regression were used to determine variables that associated with HIV infection. Demographic characteristics and behavioral factors are included in this study. Results: HIV prevalence was estimated at 6.6% among FSW. In multivariable analysis variables associated with HIV infection included: (a) young age [p=0.03; 18-24 years: AOR=2.92; 95% CI=0.89-9.57 | 25-34 years: AOR= 3.93; 95% CI=1.33-11.63]; (b) early age at first sexual intercouse [p=0.03; AOR=3.31; 95% CI=1.09-10.05]; (c) condom use [p=0.03; AOR-0.10; 95% CI=0.01-0.81]. Conclusion: Young FSW are at higher risk to be infected with HIV. Meanwhile, young FSW with HIV are also at high-risk of having other diseases, such as Human Papillomavirus (HPV) and cervical cancer. Therefore, for FSW, it is necessary to routinely do medical check up for HIV and other sexually transmitted infection so that they can be treated early.

Abstrak :
This book is a concise, easy to read professional text with a focus on practical aspects. All chapters include tables on sex/gender differences in symptoms and management and a series of suggestions to the novice in the field. Chapters are specialty-specific. The focus is not on women’s health, but the presentation of differences in clinical symptoms, management and outcomes in women and men. Gender Medicine strives to employ the knowledge about these differences to improve diagnosis, better understand pathogenesis and advance patient-oriented therapy.

Abstrak :
This is the very first book to deal with sex and gender differences in drug therapy - an increasingly recognized medical need. It starts with an overview on S/G in clinical syndromes and a documentation of the medical and socioeconomic damage caused by gender specific adverse drug effects. Part I covers S/G differences in pharmacokinetics. Researchers will be satisfied by the detailed discussion of the mechanisms of S/G differences in drug effects that represents cutting edge science and includes interaction of drugs with sex hormones, genomic and epigenetic mechanisms. It also covers S/G in drug development, in animal models and clinical development and S/G in drug prescriptions. Part II targets S/G differences in drug effects in cardiovascular, pulmonary, CNS, neuromuscular, neuropsychiatric and metabolic diseases, in cancer, inflammation, and rheumatic diseases, in bacterial and retroviral infections, thrombosis, embolism. New drugs will be discussed.